26.4.2021 17:29:33 CEST | Monsenso |
Ledende medarbejderes transaktioner
Selskabsmeddelelse nr. 11-2021
København, den 26. april 2021
Monsenso A/S meddeler hermed, som opfølgning på selskabsmeddelelse nr. 10 om udstedelse af warrants til direktion og medarbejdere, yderligere detailer om direktionens tildeling af warrants:
Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne:
Navn
Thomas Lethenborg
Årsag til indberetningen:
Stilling/titel:
CEO
Første indberetning/ændring:
Første indberetning
Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførende:
Navn:
Monsenso A/S
LEI-kode:
52990024UWU19T5URJ57
Nærmere oplysninger om transaktionen/transaktionerne:
Instrumenttype:
Aktier
Identifikationskode:
ISIN DK0061277977
Transaktionens art:
Tildeling af warrants
Pris(er):
DKK 5,86/aktie
Mængde(r):
100.000
Aggregeret mængde:
N/A
Aggregeret pris:
N/A
Dato for transaktionen:
2021-04-23
Sted for transaktionen:
Nasdaq First North Growth Market Denmark
Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til:
Monsenso:
Chairman of the boardMaria HjorthTel. +45 25 55 63 39E-mail: maria.hjorth@gmail.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF ApSJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning for mentale lidelser. Vores mission er at bidrage til bedre mental sundhed til flere personer og lavere omkostninger. Vores løsning bidrager til optimering af behandlingen for psykiske lidelser og giver et detaljeret overblik over patienters mentale sundhed via indsamling af data om mental tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig opsporing og intervention. Baseret på vedvarende forskning og udvikling er vores team opsat på at udvikle løsninger, der passer ind i brugernes liv, øger patienters livskvalitet og forbedrer effekten af behandlingen. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
26.4.2021 17:29:33 CEST | Monsenso |
Managers' transactions
Company announcement no. 11-2021
Copenhagen, 2021.04.26
With reference to company announcement no. 10 regarding the issuance of warrants to the management and employees, Monsenso A/S hereby reports further details on granting of warrants to the management.
Details of the person discharging managerial responsibilities/person closely associated:
Name
Thomas Lethenborg
Reason for the notification:
Position/status:
CEO
Initial notification/Amendment:
Initial notification
Details of the issuer, emmision allowance market participant, auction platform, auctioneer or auction monitor:
Name:
Monsenso A/S
LEI code:
52990024UWU19T5URJ57
Details of the transaction(s):
Description of instrument
Shares
Identification code
ISIN DK0061277977
Nature of transaction
Granting of warrants
Price(s)
DKK 5.86/share
Volume(s)
100,000
Aggregated volume
N/A
Aggregated price
N/A
Date of the transaction
2021-04-23
Place of the transaction
Nasdaq First North Growth Market Denmark
Any requiries regarding this notice should be directed to:
Monsenso
Chairman of the boardMaria HjorthTel. +45 25 55 63 39E-mail: maria.hjorth@gmail.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser
Norden CEF ApSJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
